文献速递中医内科中药与中成药合理使用

七种中成药治疗早期糖尿病肾病的网状Meta分析比较

Comparative efficacy of seven Chinese patent medicines for early diabetic kidney disease: A Bayesian network meta-analysis.
PubMed 文献 · Complement Ther Med · 2022-04-07

该贝叶斯网状Meta分析纳入62项RCT共5362例早期糖尿病肾病患者,比较七种中成药联合ACEI/ARB的疗效。结果显示百令胶囊联合方案在甘油三酯、总胆固醇及C反应蛋白方面可能更优,尿毒清颗粒、金水宝、复方血栓通胶囊、黄葵胶囊分别在降低UAER、24h尿蛋白、血肌酐、尿素氮方面排序靠前,但证据确定性多为低或极低。

要点

  • 尿毒清颗粒联合ACEI/ARB在降低UAER方面排序最优(SUCRA 92%)。
  • 金水宝联合方案在降低24h尿蛋白方面排序最优(SUCRA 97%)。
  • 百令胶囊联合方案在降低甘油三酯、总胆固醇及CRP方面可能更优。

核心结论

  • 中成药联合ACEI/ARB可能对早期糖尿病肾病患者有益,但需更多高质量头对头试验确认。

研究设计与样本

  • 贝叶斯网状Meta分析,纳入62项RCT共5362例早期糖尿病肾病患者,检索至2021年3月14日。

主要发现

  • 尿毒清颗粒+ACEI/ARB降低UAER的MD为32.25(95%CrI 19.11-45.67,低确定性),SUCRA 92%。
  • 金水宝+ACEI/ARB降低24h尿蛋白的MD为76.92(95%CrI 53.54-100.58,低确定性),SUCRA 97%。
  • 复方血栓通胶囊+ACEI/ARB降低血肌酐的MD为26.02(95%CrI 6.10-45.95,低确定性),SUCRA 96%。
  • 黄葵胶囊+ACEI/ARB降低尿素氮的MD为1.46(95%CrI 0.42-2.54,极低确定性),SUCRA 86%。
  • 百令胶囊+ACEI/ARB降低甘油三酯的MD为-1.17(95%CrI -1.93至-0.43,低确定性),SUCRA 90%。

关键数值与推荐

  • 尿毒清颗粒+ACEI/ARB为降低UAER的潜在优选干预(SUCRA 92%)。
  • 金水宝+ACEI/ARB为降低24h尿蛋白的潜在优选干预(SUCRA 97%)。
  • 复方血栓通胶囊+ACEI/ARB为降低血肌酐的潜在优选干预(SUCRA 96%)。
  • 黄葵胶囊+ACEI/ARB为降低尿素氮的潜在优选干预(SUCRA 86%)。
  • 百令胶囊+ACEI/ARB对降低甘油三酯、总胆固醇和CRP可能更优(SUCRA分别为90%、90%、76%)。

临床怎么用

  • 临床可参考排序结果,根据早期糖尿病肾病患者主要异常指标选择相应中成药联合ACEI/ARB。
  • 选用时需结合证据确定性等级,低或极低确定性结果不宜作为强推荐依据。

局限性

  • 多数结局证据确定性为低或极低,需更多高质量、大样本、多中心RCT及头对头试验验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Bailing Capsule (BLC), Jinshuibao (JSB), Huangkui Capsule (HKC), Uremic Clearance Granule (UCG), Tripterygium glycosides (TG), Compound Xueshuantong Capsule (CXC), and Shenyan Kangfu Tablet (SYKFT) as classic Chinese patent medicines (CPMs), have been widely used and shown beneficial effects on the treatment of early diabetic kidney disease (DKD). However, the comparative efficacy of seven CPMs in the treatment of early DKD remains unknown. OBJECTIVE: To evaluate and compare the efficacy of seven CPMs (BLC, JSB, HKC, UCG, TG, CXC, SYKFT) combined with angiotensin-converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB) on early DKD by a Bayesian network meta-analysis (NMA) of randomized controlled trials (RCTs). METHODS: A comprehensive and systematic literature search was performed in PubMed, Embase, Cochrane Library, Web of Science, Clinical Trials.gov, China Biology Medicine, Chinese National Knowledge Infrastructure, Chinese Scientific Journal, and Wanfang databases from inception to March 14, 2021, for full-text RCTs that evaluated the efficacy of seven CPMs combined with ACEI/ARB on patients with early DKD. Two reviewers independently screened studies for eligibility, extracted data, and assessed the risk of bias. Agreement between reviewers was measured using kappa statistics. Mean difference (MD) and odds ratio (OR) were calculated to evaluate continuous variables and dichotomous, respectively. The random effect modeling NMA was performed and the ranking probability of interventions in various outcomes was also conducted based on the surface under the cumulative ranking curve (SUCRA). Begg's and Egger's tests were used to evaluate publication bias. The certainty of the evidence for outcomes was evaluated according to the GRADE system. RESULTS: A total of 62 RCTs with 5362 patients with early DKD were identified. The value of Kappa calculated for the various parameters extracted by the two investigators was 0.821 (P < 0.001). Among these CPMs, UCG + ACEI/ARB showed the best effectiveness for urinary albumin excretion rate (UAER) (MD 32.25, 95% CrI 19.11-45.67, low certainty) with SUCRA 92%. JSB + ACEI/ARB showed the highest effectiveness for 24-h urinary total protein (24-h UTP) (MD 76.92, 95% CrI 53.54-100.58, low certainty) with SUCRA 97%. CXC + ACEI/ARB showed the highest effectiveness for serum creatinine (SCr) (MD 26.02, 95% CrI 6.10-45.95, low certainty) with SUCRA 96%. HKC + ACEI/ARB showed the highest effectiveness for blood urea nitrogen (BUN) (MD 1.46, 95% CrI 0.42-2.54, very low certainty) with SUCRA 86%. BLC + ACEI/ARB showed significant differences in triglyceride (TRIG) (MD - 1.17, 95% CrI - 1.93 to - 0.43, low certainty) with SUCRA 90%, total cholesterol (TC) (MD - 1.17, 95% CrI - 1.97 to - 0.39, very low certainty) with SUCRA 90%, and C-reaction protein (CRP) (MD - 0.90, 95% CrI - 1.51 to - 0.32, very low certainty) with SUCRA 76%. CONCLUSIONS: CPMs + ACEI/ARB might be positive efficacious interventions from which patients with DKD will derive benefit. UCG + ACEI/ARB, JSB + ACEI/ARB, CXC + ACEI/ARB, and HKC + ACEI/ARB might be potentially the preferred intervention for reducing UAER, 24-h UTP, SCr, and BUN levels, respectively. BLC + ACEI/ARB has a better impact on lowing TRIG, TC, and CRP levels in patients with early DKD. However, more high-quality, large-scale, multi-center RCTs and stronger head-to-head trials are required to confirm these findings.

来源:Complement Ther Med,查看原文。版权归原作者所有。

引用

  1. Zhao J, Ai J, Mo C, et al. Comparative efficacy of seven Chinese patent medicines for early diabetic kidney disease: A Bayesian network meta-analysis. Complement Ther Med. 2022. PMID: 35398481. doi:10.1016/j.ctim.2022.102831

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。